En bref: Vertex, Sandoz, Naobios, Pfizer
2023-12-15 15:00:00 Vertex signs licensing agreement with Editas Medicine Vertex has just signed a licensing agreement with the American biotech Editas Medicine for its Cas9 gene editing technology, CRISPR scissors. This agreement includes Casgevy (exagamglogene autotemcel), a cell therapy from Vertex approved in early December by the FDA against sickle cell disease. Thanks to this … Read more